Bone resorption predicts for skeletal complications in metastatic bone disease
Open Access
- 25 November 2003
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 89 (11) , 2031-2037
- https://doi.org/10.1038/sj.bjc.6601437
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasesCancer, 2000
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 1999
- Markers of bone resorption in patients treated with pamidronateEuropean Journal Of Cancer, 1998
- Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone diseaseAnnals of Oncology, 1997
- The Usefulness of Bone Turnover in Predicting the Response to Transdermal Estrogen Therapy in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 1997
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Metabolic effects of pamidronate in patients with metastatic bone diseaseBritish Journal of Cancer, 1996
- Advanced breast cancer: use of resources and cost implicationsBritish Journal of Cancer, 1993
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987